Phase II Trial of the CDK4 Inhibitor PD0332991 in Patients With Advanced CDK4-Amplified Well-Differentiated or Dedifferentiated Liposarcoma

PURPOSE: CDK4 is amplified in > 90% of well-differentiated (WDLS) and dedifferentiated liposarcomas (DDLS). The selective cyclin-dependent kinase 4 (CDK4)/CDK6 inhibitor PD0332991 inhibits growth and induces senescence in cell lines and xenografts. In a phase I trial of PD0332991, several patient...

詳細記述

保存先:
書誌詳細
主要な著者: Dickson, Mark A., Tap, William D., Keohan, Mary Louise, D'Angelo, Sandra P., Gounder, Mrinal M., Antonescu, Cristina R., Landa, Jonathan, Qin, Li-Xuan, Rathbone, Dustin D., Condy, Mercedes M., Ustoyev, Yelena, Crago, Aimee M., Singer, Samuel, Schwartz, Gary K.
フォーマット: Artigo
言語:Inglês
出版事項: American Society of Clinical Oncology 2013
主題:
Original Reports
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC3661937/
https://ncbi.nlm.nih.gov/pubmed/23569312
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2012.46.5476
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料